sodium phenylbutyrate
Commercial- Indications
- Urea cycle disorders
Company intelligence / Profile preview
Acer Therapeutics Inc.
Newton or Cambridge*, Massachusetts, United Stateslinkedin.com ↗
- Ownership
- Public · ACER
- Employees
- ~33
- Development stage
- Commercial
01
Overview
Acer Therapeutics has achieved FDA approval and commercial launch of OLPRUVA™ for certain UCDs. Its pivotal Phase 3 trial of EDSIVO™ in COL3A1-positive vEDS patients remains ongoing. Development of ACER-801 was paused after a Phase 2a trial in VMS and other indications. The company focuses on rare diseases with significant unmet needs.
- Therapeutic areas
- PsychiatryMetabolic DisordersWomen's HealthOncologyRare Diseases
- Modalities
- small molecules (notably sodium phenylbutyrate, celiprolol, osanetant)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Previously had agreements with Relief Therapeutics regarding OLPRUVA™Sanofi regarding osanetant rights acquisitionEmory University regarding IP on neurokinin antagonists.As of recent updates, regained worldwide rights to OLPRUVA™, excluding Europe.
04
Financials
- Market cap
- $0
- Total revenue
- $371.8K
- Enterprise value
- $17.6M
Beyond the preview
Go deeper on Acer Therapeutics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acer Therapeutics Inc..